0001193125-26-222885
SEC filingBenitec reported no revenue and a widened operating loss of -$13.6M for Q3 FY2026, driven by timing of OPMD-related payments and higher share-based compensation — consistent with its pre-commercial stage and intensified clinical investment.
Operating income for the three months ended March 31, 2026, was -$13.6M, compared to -$10.2M for the same period in 2025 — a 33.3% YoY decline. As disclosed in Item 2, this decrease was due to the timing of contract manufacturing activity and the timing of payments for the OPMD Natural History and Dosing study, partially offset by an increase in share-based compensation. The absence of revenue — $0.00 in both periods — reflects Benitec’s ongoing pre-commercial status and lack of licensing, partnership, or product-related income.
Net income was -$11.9M for Q3 FY2026, versus -$9.4M in Q3 FY2025 — a 27.6% YoY decline. Diluted EPS remained unchanged at -$0.24, indicating that while the absolute loss increased, the per-share impact was stable. This stability arises from the calculation methodology and does not imply flat underlying economics; rather, it reflects how the loss is distributed across the diluted share count under GAAP.
Net cash used in operating activities improved to -$11.6M, compared to -$15.4M in the prior-year quarter. As stated in Item 2, this improvement was primarily the result of the net loss, partially offset by non-cash expenses and changes in working capital — notably in trade and other payables. The improvement occurred despite a larger net loss, underscoring the influence of timing-related payables movements on quarterly cash flow.
Capital expenditures totaled $26,000 for the quarter, up from $18,000 YoY. This modest increase reflects continued low-level infrastructure or equipment needs tied to research operations, not expansionary investment. Free cash flow — defined as net cash provided by operating activities less capital expenditures — was -$11.6M, reinforcing that all operating cash outflow remains directed toward advancing the clinical pipeline.
Management expects research and development expenses to increase due to continued development of the OPMD program, and anticipates general and administrative expenses may also rise in support of that effort. These expectations are grounded in current clinical execution priorities, not new financing events or balance sheet metrics — all of which remain outside the authoritative financial packet and therefore excluded from this narrative. Cash management continues to prioritize liquidity and capital preservation, per stated investment policy.